| |
| |
|
| Insider
Information: |
Holles Natalie C. |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
1,276,146 |
|
|
Indirect Shares
|
2,600 |
|
|
| Direct
Value |
$13,870,354 |
|
|
|
Indirect Value
|
$2,938 |
|
|
| Total
Shares |
1,278,746 |
|
|
| Total
Value |
$13,873,292 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Hyperion Therapeutics Inc |
HPTX |
SVP, Business Developm... |
2015-05-07 |
0 |
2014-03-11 |
0 |
Premium* |
|
|
Audentes Therapeutics, Inc. |
BOLD |
President and COO |
2020-01-15 |
0 |
2017-05-31 |
0 |
Premium* |
|
|
Allakos Inc. |
ALLK |
Director |
|
0 |
2020-12-21 |
2,600 |
Premium* |
|
|
Day One Biopharmaceuticals, Inc. |
DAWN |
Director |
2021-05-26 |
57,310 |
|
0 |
Premium* |
|
|
Third Harmonic Bio, Inc. |
THRD |
|
2024-04-11 |
1,218,836 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
20 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| THRD |
Third Harmonic Bio, Inc. |
CEO |
• • – |
2024-04-11 |
4 |
AS |
$12.19 |
$165,214 |
D/D |
(13,558) |
1,218,836 |
0 |
% |
|
| THRD |
Third Harmonic Bio, Inc. |
CEO |
• • – |
2024-04-11 |
4 |
OE |
$4.20 |
$56,944 |
D/D |
13,558 |
1,232,394 |
0 |
- |
|
| THRD |
Third Harmonic Bio, Inc. |
CEOOfficer |
• • – |
2022-09-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,218,836 |
|
- |
|
| DAWN |
Day One Biopharmaceutical... |
Director |
– • – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
57,310 |
|
- |
|
| ALLK |
Allakos Inc. |
Director |
– • – |
2020-12-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,600 |
|
% |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2020-01-15 |
4 |
D |
$60.00 |
$6,266,340 |
D/D |
(104,439) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-12-12 |
4 |
D |
$59.37 |
$5,795,046 |
D/D |
(97,609) |
104,439 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-12-12 |
4 |
OE |
$2.76 |
$1,868,986 |
D/D |
147,344 |
193,367 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-12-05 |
4 |
D |
$59.21 |
$29,901 |
D/D |
(505) |
54,704 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-09-05 |
4 |
D |
$31.02 |
$15,665 |
D/D |
(505) |
55,209 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-06-05 |
4 |
D |
$37.31 |
$37,646 |
D/D |
(1,009) |
55,714 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
23,333 |
56,723 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2019-01-24 |
4 |
OE |
$2.76 |
$22,949 |
D/D |
8,300 |
33,390 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
President and COO |
• – – |
2018-06-01 |
4 |
OE |
$2.76 |
$14,073 |
D/D |
5,090 |
25,090 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Senior Vice President, COO |
• – – |
2017-05-31 |
4 |
OE |
$2.76 |
$55,200 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
SVP, Business Development |
• – – |
2015-05-07 |
4 |
D |
$46.00 |
$32,292 |
D/D |
(702) |
0 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
SVP, Business Development |
• – – |
2015-05-07 |
4 |
D |
$46.00 |
$816,500 |
D/D |
(17,750) |
0 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
SVP, Business Development |
• • – |
2015-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
18,452 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
SVP, Business Development |
• • – |
2015-01-02 |
4 |
D |
$24.28 |
$13,305 |
D/D |
(548) |
4,452 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
SVP, Business Development |
• – – |
2014-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
20 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
